Loading
Monopar Therapeutics

Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar is building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages, leveraging its scientific and clinical expertise to help reduce the risk and accelerate the clinical development of its drug product candidates.

Monopar's team is located in San Francisco, CA and Chicago, IL.

Innovative Drugs and Drug Combinations

Licensing, developing and commercializing transformative oncology therapeutics

Why Oncology?

Multiple factors drive our passion for oncology

Market Demand

The numbers behind our research define Validive and camsirubicin opportunities

Corporate Overview

Our management team has extensive experience in building companies and developing therapeutics through regulatory approval and commercialization. 

Our Research Pipeline

Monopar’s pipeline consists of Validive®(clonidine HCI MBT), a mucoadhesive buccal tablet for the prevention of chemoradiotherapy-induced severe oral mucositis (SOM) in oropharyngeal cancer (OPC) patients; camsirubicin, a proprietary analog of doxorubicin for the treatment of advanced soft tissue sarcoma, engineered specifically to minimize toxic effects on the heart while retaining anticancer activity; MNPR-101 RIT, a preclinical-stage radio-immuno-therapeutic (RIT) for the treatment of advanced solid cancers and severe COVID-19; MNPR-101, a preclinical-stage monoclonal antibody for the treatment of solid cancers; and MNPR-202, an early-stage preclinical camsirubicin analog which has potential in doxorubicin resistant cancers and as an immunogenic chemotherapy in combination with checkpoint inhibitors.



Product Indications Preclinical Phase 1 Phase 2 Phase 3 Status

Validive®

Chemoradiation induced SOM

Preclinical complete

Phase 1 complete

Phase 2 in progress

Phase 3 not started

Phase 2b/3 VOICE trial ongoing in US and EU

Camsirubicin

Advanced Soft Tissue Sarcoma

Preclinical complete

Phase 1 in progress

Phase 2 not started

Phase 3 not started

Phase 1b trial ongoing in the US

MNPR-101 RIT

Advanced Solid Cancers, Severe COVID-19

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Collaboration with NorthStar

MNPR-101

Solid Cancers

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Late preclinical

MNPR-202

Advanced Solid Cancers

Preclinical in progress

Phase 1 not started

Phase 2 not started

Phase 3 not started

Early preclinical
Email Alerts

Stay informed and receive company updates straight to your inbox